Germany approves human trials of potential vaccine by Pfizer, BioNTech
The companies are awaiting testing approval from the US as well23-04-2020
23-04-2020
PFIZER LTD. - 500680 - Board Meeting Intimation for Board Meeting For Consideration Of Declaration Of Interim Dividend For The Financial Year Ended March 31, 2020
PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/04/2020 ,inter alia, to consider and approve This is to inform you that a Meeting of Board of Directors of the Company is scheduled to be held on Monday, April 27, 2020, to consider declaration of Interim Dividend for the Financial Year ended March 31, 2020. It may also be noted that pursuant to the 'Pfizer Limited - Code of Internal Procedures and Conduct to Regulate Monitor and Report Trading by Insiders', the trading window of the Company has already been closed from Wednesday, April 1, 2020 till 48 hours after the Publication of Audited Results for the Financial Year ended March 31, 2020.22-04-2020
PFIZER LTD. - 500680 - Shareholding for the Period Ended March 31, 2020
Pfizer Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here15-04-2020
Coronavirus pandemic | 70 vaccines in development globally, 3 being tested in human trials: WHO
A WHO document shows that big pharma companies, such as Pfizer and Sanofi, have vaccine candidates in pre-clinical stage13-04-2020
PFIZER LTD. - 500680 - Compliance Certificate - Regulation 7(3) Of The SEBI (LODR) Regulations, 2015
In compliance with Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Certificate from the Company and the Registrar and Share Transfer Agent for the half year ended March 31, 2020.13-04-2020
PFIZER LTD. - 500680 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 225270 Name of the Signatory :- PRAJEET NAIRDesignation :- Company Secretary and Compliance Officer13-04-2020
PFIZER LTD. - 500680 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations,2018, we furnish herewith Certificate dated April 8, 2020, issued by KFin Technologies Private Limited, Registrar and Share Transfer Agent of the Company for the quarter ended March 31, 2020. We request you to take the same on record.13-04-2020
Early studies of potential coronavirus treatment show promise: Pfizer
It also finalised a plan to develop a coronavirus vaccine in partnership with German drugmaker BioNTech SE and said the companies hope to produce millions of vaccines by the end of 2020.11-04-2020
Pfizer says early studies of potential coronavirus treatment show promise
Pfizer first revealed plans to try to develop an antiviral compound for COVID-19 in March, and later said it was working with BioNTech SE on a potential vaccine based on messenger RNA technology.09-04-2020
PFIZER LTD. - 500680 - Pfizer Limited - News Clarification
Pfizer Limited response - News Clarification02-04-2020